These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 22123916)

  • 21. Learning the value of drugs--is rofecoxib a regulatory success story?
    Eisenberg RS
    N Engl J Med; 2005 Mar; 352(13):1285-7. PubMed ID: 15800222
    [No Abstract]   [Full Text] [Related]  

  • 22. Failing the public health--rofecoxib, Merck, and the FDA.
    Topol EJ
    N Engl J Med; 2004 Oct; 351(17):1707-9. PubMed ID: 15470193
    [No Abstract]   [Full Text] [Related]  

  • 23. Drug samples bring scrutiny.
    Taylor M
    Mod Healthc; 2005 May; 35(18):22. PubMed ID: 15898265
    [No Abstract]   [Full Text] [Related]  

  • 24. Merck's recall of rofecoxib--a strategic perspective.
    Oberholzer-Gee F; Inamdar SN
    N Engl J Med; 2004 Nov; 351(21):2147-9. PubMed ID: 15548771
    [No Abstract]   [Full Text] [Related]  

  • 25. How direct-to-consumer television advertising for osteoarthritis drugs affects physicians' prescribing behavior.
    Bradford WD; Kleit AN; Nietert PJ; Steyer T; McIlwain T; Ornstein S
    Health Aff (Millwood); 2006; 25(5):1371-7. PubMed ID: 16966735
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Will Merck survive Vioxx?
    Simons J; Stipp D
    Fortune; 2004 Nov; 150(9):90-2, 94, 96-7 passim. PubMed ID: 15543824
    [No Abstract]   [Full Text] [Related]  

  • 27. Eli Lilly settles corrupt foreign practices complaint for $29.4m.
    Roehr B
    BMJ; 2012 Dec; 345():e8694. PubMed ID: 23271750
    [No Abstract]   [Full Text] [Related]  

  • 28. 94% of patients suing Merck over rofecoxib agree to company's offer.
    Charatan F
    BMJ; 2008 Mar; 336(7644):580-1. PubMed ID: 18340064
    [No Abstract]   [Full Text] [Related]  

  • 29. Don't blame it all on the bogey.
    Day M
    BMJ; 2007 Jun; 334(7606):1250-1. PubMed ID: 17569929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rofecoxib, Merck, and the FDA.
    Kim PS; Reicin AS
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625342
    [No Abstract]   [Full Text] [Related]  

  • 31. Drug firms back-pedal on direct advertising.
    Nature; 2005 Aug; 436(7053):910-1. PubMed ID: 16107811
    [No Abstract]   [Full Text] [Related]  

  • 32. [Vision impairment by COX-2 inhibitor and the sequelae of voluntary Vioxx recall].
    Meyer CH
    Klin Monbl Augenheilkd; 2005 Jan; 222(1):62-3. PubMed ID: 15678404
    [No Abstract]   [Full Text] [Related]  

  • 33. Recent developments in health law. Merck and the Vioxx decision: playing by the changing rules of the chemical exposure game.
    Cohen JG
    J Law Med Ethics; 2005; 33(4):866-9. PubMed ID: 16686256
    [No Abstract]   [Full Text] [Related]  

  • 34. US drug industry bans expensive freebies for MDs, Canada raises fines.
    Sibbald B
    CMAJ; 2002 Sep; 167(5):522. PubMed ID: 12240824
    [No Abstract]   [Full Text] [Related]  

  • 35. Rofecoxib, Merck, and the FDA.
    Villalba L; Witter J
    N Engl J Med; 2004 Dec; 351(27):2875-8; author reply 2875-8. PubMed ID: 15625745
    [No Abstract]   [Full Text] [Related]  

  • 36. Court hears how drug giant Merck tried to "neutralise" and "discredit" doctors critical of Vioxx.
    Moynihan R
    BMJ; 2009 Apr; 338():b1432. PubMed ID: 19349350
    [No Abstract]   [Full Text] [Related]  

  • 37. Novo Nordisk pays $58.7m to settle claims of mis-selling liraglutide.
    Dyer O
    BMJ; 2017 Sep; 358():j4214. PubMed ID: 28887314
    [No Abstract]   [Full Text] [Related]  

  • 38. Commentary on payment and reimbursement issues affecting the marketing of drugs, medical devices, and biologics, with emphasis on the anti-kickback statute and Stark II.
    Reiss JB
    Food Drug Law J; 1997; 52(1):99-108. PubMed ID: 10346713
    [No Abstract]   [Full Text] [Related]  

  • 39. Drug safety: are we making progress?: comment on "pooled analysis of rofecoxib placebo-controlled clinical trial data".
    Luepker RV
    Arch Intern Med; 2010 Jan; 170(2):202. PubMed ID: 20101016
    [No Abstract]   [Full Text] [Related]  

  • 40. Former drug execs lose appeal. Bid for re-entry to Medicare is denied.
    Rhea S
    Mod Healthc; 2010 Dec 20-27; 40(51):14. PubMed ID: 21344720
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.